Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Califf

Showing results (521-530 of 567) with videos related to

Pageof 57
Sort By:
The New England Journal of Medicine|October 31, 1996
Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA InvestigatorsE M Ohman, P W Armstrong, R H Christenson, et al.
Circulation|May 21, 1998
Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries TrialA M Ross, K S Coyne, E Moreyra, et al.
American Heart Journal|July 1, 1997
A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST)R M Califf, K F Adams, W J McKenna, et al.
The American Journal of Cardiology|December 14, 2001
Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary interventionM T Roe, C B Granger, J A Puma, et al.
Circulation|August 15, 1996
Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC InvestigatorsD B Mark, J D Talley, E J Topol, et al.
JAMA|January 27, 2000
Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin TherapyJ H Alexander, R A Sparapani, K W Mahaffey, et al.
Circulation|April 20, 1999
Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockadeA M Lincoff, J E Tcheng, R M Califf, et al.
The American Journal of Cardiology|June 27, 2000
Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial)A Barbagelata, R M Califf, E B Sgarbossa, et al.
Circulation|October 7, 1998
Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhageM A Sloan, C A Sila, K W Mahaffey, et al.
The American Journal of Cardiology|June 26, 2001
Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trialS M Al-Khatib, K S Pieper, K L Lee, et al.
Pageof 57

Showing results (521-530 of 567) with videos related to

Sort By:
Pageof 57
The New England Journal of Medicine|October 31, 1996
Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA InvestigatorsE M Ohman, P W Armstrong, R H Christenson, et al.
Circulation|May 21, 1998
Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries TrialA M Ross, K S Coyne, E Moreyra, et al.
American Heart Journal|July 1, 1997
A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST)R M Califf, K F Adams, W J McKenna, et al.
The American Journal of Cardiology|December 14, 2001
Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary interventionM T Roe, C B Granger, J A Puma, et al.
Circulation|August 15, 1996
Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC InvestigatorsD B Mark, J D Talley, E J Topol, et al.
JAMA|January 27, 2000
Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin TherapyJ H Alexander, R A Sparapani, K W Mahaffey, et al.
Circulation|April 20, 1999
Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockadeA M Lincoff, J E Tcheng, R M Califf, et al.
The American Journal of Cardiology|June 27, 2000
Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial)A Barbagelata, R M Califf, E B Sgarbossa, et al.
Circulation|October 7, 1998
Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhageM A Sloan, C A Sila, K W Mahaffey, et al.
The American Journal of Cardiology|June 26, 2001
Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trialS M Al-Khatib, K S Pieper, K L Lee, et al.
Pageof 57